Gestational trophoblastic disease: what have we learned in the past decade?

Article Abstract:

Trophoblastic tumors are cancers of the uterus derived from fetal chorion. Types of trophoblastic tumors include hydatidiform moles (molar pregnancy), invasive moles and choriocarcinomas. The hydatidiform mole is the beginning stage of disease and choriocarcinoma is the more advanced form. Hydatidiform moles can be complete, without an embryo or fetus with a even number of chromosomes (diploid 46, XX or 46, XY) or partial, with a fetus and a triploid number of chromosomes. Complete moles are more cancerous than partial moles. A diploid 46, XY configuration carried the greatest risk of cancer. Tests for markers in the blood can used to detect trophoblastic tumors. These include measuring free human chorionic gonadotropin (hCG), fragments of hCG and acid variants of hCG. These markers can be used to monitor disease progression and predict prognosis. Complex chemotherapeutic regimens, radiotherapy and surgery are required in patients termed ultra-high-risk because of the poor prognosis. Prognosis depends on the disease classification of the patient. The ultra-high-risk patients represent 10 to 20 percent of those who die from the disease. Etoposide and cisplatin chemotherapeutic agents are valuable drugs used to treat advanced gestational trophoblastic tumors. (Consumer Summary produced by Reliance Medical Information, Inc.)

Care and treatment, Chemotherapy, Molar pregnancy, Hydatidiform mole

---

Levels of placenta growth factor in gestational trophoblastic diseases

Article Abstract:

Women with elevated blood levels of placenta growth factor may have gestational trophoblastic disease, according to a study of 225 women. Gestational trophoblastic disease is an abnormal growth of the fetal membranes, which can become cancerous. An increase in the amount of placenta growth factor relative to human chorionic gonadotropin is an especially good indicator of gestational trophoblastic disease.

Physiological aspects, Growth factors, Trophoblastic tumours

---

Single-dose methotrexate regimen in the treatment of low-risk gestational trophoblastic neoplasia

Article Abstract:

The effectiveness of single-dose methotrexate in women with low-risk gestational trophoblastic neoplasia is evaluated. The results have shown that this regimen offers an effective option for women with low-risk gestational trophoblastic neoplasia without metastases and a low pretreatment human chorionic gonadotropin level.

Science & research, Research, Dosage and administration, Chorionic gonadotropin, Chorionic gonadotropins, Methotrexate, Clinical report

Similar abstracts:

• Abstracts: Sexually transmitted disease: shadow on the land, revisited
• Abstracts: The association of genital ulcer disease and HIV infection at a dermatology-STD clinic in Uganda. High-titer positive nontreponemal tests with negative specific treponemal serology in patients with HIV infection and/or intravenous substance use
• Abstracts: Nucleolar organiser regions: new prognostic variable in breast carcinomas. Expression of epidermal growth factor receptor in breast carcinoma
• Abstracts: Maturation of the secretion of thyroid hormone and thyroid-stimulating hormone in the fetus. Immunoendocrine interactions and autoimmunity
• Abstracts: Hypoaldosteronism - disease or normal response? Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.